Highlights
RUNX1 familial platelet disorder (RUNX1-FPD) carries a substantial lifetime risk of hematologic malignancy, ranging from 35% to 50%, yet current clinical practice lacks consensus on preventive interventions. This article presents a groundbreaking case of preemptive allogeneic hematopoietic stem cell transplantation (HSCT) in a RUNX1-FPD patient and introduces a structured shared decision-making framework designed to help patients, families, and clinicians navigate this complex therapeutic crossroads. The framework systematically evaluates germline and somatic genetic factors, clonal evolution patterns, family history, quality-of-life considerations, and donor availability to inform personalized timing decisions.
Background: Understanding RUNX1-FPD and Its Malignant Potential
RUNX1 familial platelet disorder represents one of the most common germline hematologic malignancy predisposition syndromes identified to date. The RUNX1 gene encodes a critical transcription factor essential for normal hematopoietic development, and germline mutations disrupt this regulatory machinery, leading to impaired platelet function and increased susceptibility to malignant transformation. Patients with RUNX1-FPD typically present with thrombocytopenia and platelet dysfunction from childhood, though the severity of bleeding manifestations varies considerably among affected individuals.
The natural history of RUNX1-FPD is characterized by progressive clonal hematopoiesis, with many patients developing measurable clones carrying additional somatic mutations over time. These somatic hits can affect genes involved in the cohesin complex, signaling pathways, and epigenetic regulation, progressively increasing the risk of progression to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Unlike sporadic hematologic malignancies, RUNX1-FPD offers a unique window of opportunity—early detection through genetic screening enables intervention before overt malignant transformation occurs.
Allogeneic hematopoietic stem cell transplantation remains the only curative option for RUNX1-FPD, as it can eliminate both the germline predisposition and any existing malignant clones. However, HSCT carries significant morbidity and mortality risks, including graft-versus-host disease, infections, and treatment-related complications. The fundamental challenge lies in identifying the optimal timing for transplantation—early enough to prevent malignancy development while avoiding unnecessary transplant-related risks in patients who might never progress.
Case Presentation: A Family Confronting Inherited Risk
The published case describes an individual with confirmed RUNX1-FPD who had a compelling family history of hematologic malignancy, including multiple affected relatives across generations. This family context profoundly influenced the decision-making process, as the patient had witnessed the devastating progression of disease in close family members. The presence of this strong family history represented a significant risk factor, suggesting potentially more aggressive underlying biology in this particular lineage.
Comprehensive genetic characterization revealed the germline RUNX1 mutation along with early clonal changes detectable through sensitive molecular techniques. Serial monitoring demonstrated clonal evolution over time, with acquisition of additional somatic variants that are known to be associated with malignant progression in RUNX1-FPD. These findings provided objective evidence supporting concern for imminent transformation, strengthening the argument for preemptive intervention rather than continued surveillance.
Beyond the genetic considerations, the patient experienced clinically significant bleeding manifestations that substantially impacted quality of life. Recurrent epistaxis, menorrhagia, and impaired wound healing contributed to functional limitations and psychological burden. These quality-of-life factors were explicitly incorporated into the decision-making framework, as the potential benefits of HSCT extended beyond malignancy prevention to include improvement in platelet function and bleeding complications.
The Shared Decision-Making Framework
The investigators developed a structured framework organized around six key domains that influence the decision to pursue preemptive HSCT versus continued surveillance in RUNX1-FPD. This framework emphasizes shared decision-making that integrates clinical evidence with patient values and preferences, recognizing that the optimal choice varies substantially among individuals based on their unique circumstances and priorities.
Germline and Somatic Variant Analysis
The framework prioritizes comprehensive genetic characterization as the foundation for decision-making. This includes confirmation of the specific RUNX1 mutation, assessment of its functional consequences, and identification of any co-existing somatic variants within the hematopoietic clone. Certain somatic mutations, particularly those affecting genes involved in cohesin complex function or signaling pathways, confer higher transformation risk and may favor earlier intervention. The framework incorporates current evidence on genotype-phenotype correlations while acknowledging significant knowledge gaps regarding mutation-specific risks.
Clonal Evolution Monitoring
Longitudinal monitoring of clonal dynamics provides critical information for timing decisions. The framework recommends serial assessment using sensitive techniques capable of detecting clonal expansion before morphological evidence of malignancy appears. Key parameters include clone size, rate of expansion, and acquisition of new somatic mutations. A rapidly expanding clone or emergence of high-risk somatic variants may justify more aggressive intervention, while stable clones may permit continued surveillance.
Familial History Assessment
Family history serves as an important prognostic indicator in RUNX1-FPD. Families with multiple affected members, early-onset malignancies, or specific patterns of hematologic disease demonstrate inherent biological factors that influence risk. The framework incorporates detailed family history analysis to identify high-risk pedigrees where preemptive transplantation may be particularly strongly indicated. Conversely, patients from families with late-onset or solitary cases may benefit from more conservative management initially.
Early Morphologic and Hematologic Features
Subtle hematologic abnormalities often precede overt malignant transformation. The framework emphasizes careful evaluation of peripheral blood counts, red cell indices, and morphological review of blood and bone marrow smears. Unexplained cytopenias, dysplastic features, or increasing blast percentages warrant thorough investigation and may shift the balance toward transplantation. Close collaboration between hematology and pathology specialists is essential for accurate interpretation of these findings.
Bleeding-Related Quality of Life Impact
The framework explicitly incorporates patient-reported outcomes related to bleeding manifestations. Severe or symptomatic bleeding that impairs daily activities, restricts occupational function, or causes psychological distress represents a legitimate indication for considering HSCT independent of malignancy risk. Patients experiencing significant quality-of-life impairment from platelet dysfunction may derive substantial benefit from transplantation, potentially justifying intervention at lower absolute malignancy risk thresholds.
Donor Availability and Logistics
Practical considerations regarding donor availability substantially influence the feasibility of preemptive transplantation. The framework recommends early identification and evaluation of potential donors, including matched related donors, matched unrelated donors, and alternative sources such as cord blood or haploidentical donors. Delays in donor identification may necessitate earlier intervention while donor options remain available, while patients with readily identified donors may have greater flexibility in timing.
Risks and Ethical Considerations
Preemptive HSCT in RUNX1-FPD carries substantial risks that must be carefully weighed against potential benefits. Transplant-related mortality remains a significant concern, with contemporary series reporting rates of 5-15% depending on donor source and patient characteristics. Graft-versus-host disease affects a substantial proportion of recipients, potentially causing chronic morbidity and reducing quality of life. Long-term complications including secondary malignancies, cardiovascular disease, and endocrine dysfunction further contribute to the burden of transplantation.
The ethical dimensions of preemptive transplantation in a condition with incomplete penetrance are particularly complex. Unlike conditions with near-certain malignant transformation, RUNX1-FPD means that many affected individuals will never develop hematologic malignancy, yet currently available risk-stratification tools cannot reliably identify which patients will progress. This uncertainty creates ethical tension between the imperative to prevent serious disease and the responsibility to avoid causing harm through unnecessary intervention.
The framework addresses these ethical challenges by emphasizing several key principles. First, decision-making should be thoroughly informed, ensuring patients and families understand both the risks of transplantation and the uncertainties in natural history prediction. Second, patient values and preferences must guide final decisions, particularly regarding the relative weight given to malignancy prevention versus treatment risks. Third, decisions should be reconsidered over time as new clinical data emerge, recognizing that optimal timing may change as understanding of individual risk evolves.
Expert Commentary and Future Directions
This case and framework represent an important step toward evidence-based management of germline hematologic malignancy predisposition syndromes. The ability to identify RUNX1-FPD patients before malignant transformation creates unprecedented opportunities for disease prevention, but clinical implementation requires careful refinement of risk stratification approaches. Current evidence suggests that clonal evolution patterns may serve as better predictors of imminent transformation than static genetic testing alone, highlighting the importance of longitudinal monitoring programs.
Several knowledge gaps limit current risk prediction accuracy. The natural history of RUNX1-FPD remains incompletely characterized, with limited data on long-term outcomes in well-defined cohorts. The functional significance of many RUNX1 mutations is unknown, and genotype-phenotype correlations require further investigation. Additionally, the optimal frequency and methods for clonal monitoring have not been established through prospective studies.
Future collaborative research efforts should focus on developing validated risk prediction models that integrate multiple clinical, genetic, and longitudinal parameters. International registries capturing standardized data on RUNX1-FPD patients followed prospectively would substantially advance understanding of disease natural history. Mechanistic studies exploring the biological pathways linking RUNX1 haploinsufficiency to malignant transformation may identify novel biomarkers and therapeutic targets.
Conclusion
Preemptive HSCT represents a potentially practice-changing approach to managing RUNX1-FPD, offering the possibility of cure before hematologic malignancy develops. The shared decision-making framework presented here provides a structured, patient-centered approach for navigating this complex clinical decision. By systematically evaluating genetic factors, clonal evolution, family history, quality of life, and practical considerations, clinicians can work with patients and families to determine individualized optimal management strategies. As understanding of RUNX1-FPD biology continues to advance, refinement of risk stratification approaches will enhance the precision of these decisions, ultimately improving outcomes for individuals affected by this inherited predisposition syndrome.
Funding and ClinicalTrials.gov
This research was supported by institutional funding and collaborative research agreements. The authors declare no conflicts of interest relevant to this work.
References
1. Olson TS, Ericson K, Antin JH, et al. Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework. Haematologica. 2026. PMID: 41924923.
2. Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2017;2017:325-332.
3. Churpek JE, Godley LA. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2018;132(21):2227-2240.
4. Bannon SA, DiNardo CD. Inherited thrombocytopenia and platelet disorders. Hematology Am Soc Hematol Educ Program. 2021;2021:221-228.